Roche Offers Rx/Dx Pipeline Update at UBS Life Sciences Conference

A Roche official said that a primary focus for the company is launching drug/diagnostic combination treatments through its personalized healthcare franchise, since such products are differentiated from others on the market, may go through regulatory approval faster, and justify higher pricing.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.